3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Endometrial Neoplasms
7
Lymphatic Metastasis
5
Uterine Cervical Neoplasms
4
Urinary Bladder Neoplasms
3
Breast Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Uterine Neoplasms
1
Urologic Neoplasms
1
Ureteral Neoplasms
1
Thyroid cancer, follicular
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Recurrence
1
Radiation Injuries
1
Prostate Adenocarcinoma
1
Postoperative Complications
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Mixed Tumor, Mesodermal
1
Melanoma
1
Lymphedema
1
Interventions
Cyclophosphamide
115
Dexamethasone
70
fludarabine phosphate
57
Cytarabine
56
fludarabine
52
Rituximab
51
Peripheral Blood Stem Cell Transplantation
40
Etoposide
40
Gemcitabine
39
Lenalidomide
38
pembrolizumab
33
Radiotherapy
33
Busulfan
33
Filgrastim
32
Carboplatin
31
Methotrexate
30
Cyclosporine
29
Cisplatin
29
Bortezomib
29
Mycophenolic Acid
28
Melphalan
28
venetoclax
27
Paclitaxel
26
Whole-Body Irradiation
24
Antilymphocyte Serum
23
Temozolomide
22
Granulocyte Colony-Stimulating Factor
20
Calcium Dobesilate
20
Bevacizumab
20
Tacrolimus
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Recurrence
×
Lymph Node Excision
×
Clear all
NCT03230201
2017-08-08
UTUC
Peking University First Hospital
Phase NA
Unknown
80 enrolled